Alexion develops breakthrough therapies for people living with rare diseases. As part of AstraZeneca, the company translates complex science into medicines addressing conditions affecting hundreds of millions globally, many with limited or no treatment options. Its work spans haematology, neurology, nephrology, cardiology, and other areas, grounded in decades of pioneering research into the complement system. The company partners with patients, caregivers, researchers, and advocates to integrate lived experience into every stage of development. Driven by urgency and patient centricity, Alexion works to shorten diagnosis pathways, advance clinical trials, and deliver transformative outcomes that help people fully live their best lives.
5000
Team Members
1992
Founded
Pharma
Sector
Hybrid
Work Environment
A world where rare diseases no longer limit potential, where every patient has access to transformative treatments, and where scientific innovation delivers hope and meaningful outcomes for people and families affected by devastating conditions.
At Alexion, our mission is to transform the lives of people affected by rare diseases and devastating conditions by continuously innovating and creating meaningful value in all that we do.